ENVERIC BIOSCIENCES, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.8M | $-9.6M | $-17.3M | $-18.5M | $-49.0M | $-6.9M | $-2.4M | $-16.9M |
| Depreciation & Amortization | $200.9K | $337.5K | $344.0K | $327.9K | $656.6K | $120.9K | $2.3M | $2.9M |
| Depreciation | $158.7K | $168.7K | $175.2K | $159.2K | $13.3K | — | — | — |
| Amortization | $42.2K | $168.8K | $168.8K | $168.8K | $643.3K | $120.9K | $2.3M | $2.9M |
| Stock-Based Compensation | $827.3K | $1.6M | $2.2M | $2.6M | $12.6M | $2.0M | $624.1K | — |
| Net Cash from Operating Activities | $-8.1M | $-7.7M | $-14.1M | $-17.1M | $-11.5M | $-3.9M | $-647.9K | $-2.6M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $5.2K | $584.2K | $189.7K | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | $200.0K | $3.6M |
| Net Cash from Investing Activities | — | — | $11.7K | $-584.2K | $2.2M | $-44.1K | $-284.3K | $-3.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $10.6M | $7.7M | $-1.3M | $18.2M | $24.9M | $5.5M | $560.0K | $2.7M |
| Net Change in Cash | $2.4M | $-47.0K | $-15.4M | $367.9K | $15.8M | $1.5M | $-70.0K | $-3.5M |
| Free Cash Flow | — | — | $-14.1M | $-17.7M | $-11.6M | — | — | — |